Formulary
Peginterferon beta-1a: Indications, Dosing, Side Effects and Interactions
For peginterferon beta-1a Peginterferon beta-1a is a polyethylene glycol-conjugated ('pegylated') derivative of interferon beta; pegylation increases the...
MedNext Academy | 3 min read
Peginterferon beta-1a: Indications, Dosing, Side Effects and Interactions
For peginterferon beta-1a Peginterferon beta-1a is a polyethylene glycol-conjugated ('pegylated') derivative of interferon beta; pegylation increases the...
Drug action
For peginterferon beta-1a Peginterferon beta-1a is a polyethylene glycol-conjugated ('pegylated') derivative of interferon beta; pegylation increases the persistence of interferon in the blood.
Indications and dose
**Treatment of relapsing, remitting multiple sclerosis**
- **Adult** (By Subcutaneous Injection): (consult product literature).
Cautions
For peginterferon beta-1a History of cardiac disorders; history of depressive disorders (avoid in severe depression or in those with suicidal ideation); history of seizures; history of severe myelosupression Cautions, further information Consult product literature for further information about cautions.
Contraindications
For peginterferon beta-1a Severe depression; suicidal ideation
Side effects
For peginterferon beta-1a Common or very common Arthralgia; asthenia; chills; depression; fever; headache; hyperthermia; influenza like illness; myalgia; nausea; pain; skin reactions; vomiting Uncommon Seizure; thrombocytopenia Rare or very rare Glomerulosclerosis; haemolytic uraemic syndrome; injection site necrosis; nephrotic syndrome; thrombotic microangiopathy Frequency not known Pulmonary arterial hypertension
Pregnancy
For peginterferon beta-1a Do not initiate during pregnancy. Avoid unless potential benefit outweighs risk.
Breast feeding
For peginterferon beta-1a Avoid-no information available.
Hepatic impairment
For peginterferon beta-1a Manufacturer advises caution in severe hepatic impairment.
Renal impairment
For peginterferon beta-1a Use with caution in severe renal impairment. M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Peginterferon beta-1a in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

